Stock Taper
SCREENER COMPARE ANY 2 STOCKS
RARE
ULTRAGENYX PHARMACEUTICAL INC.
NASDAQ
$25.61
▼ DOWN 2.48% (-0.65)

KEY STATISTICS

Market Cap$2.52 B
52w High$39.89
52w Low$18.29
Dividend Yield—
Frequency—
P/E-4.39
Volume1.61M
Shares Out.98.49M

COMPANY

LEADERSHIP

Emil D. Kakkis
CHIEF EXECUTIVE
Emil D. Kakkis

COMPENSATION 2026

Salary$861,100
Stock Awards$8,364,938
Incentive Plan Pay$299,663
All Other Comp.$32,478
Total$11,405,535

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 31, 2014
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
1,371

PRICE TARGET

Target High$83.00
Target Low$30.00
Target Median$46.50
Target Consensus$51.88

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$184.06M
NOV
3
TUE

PRICE

$25.61 ▼ DOWN 2.48% (−$0.65)
$25.50$25.80$26.10$26.409:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM25.61

About Ultragenyx Pharmaceutical Inc.

https://www.ultragenyx.com ↗

Ultragenyx Pharmaceutical Inc. develops and commercializes innovative therapies for rare and ultra-rare genetic diseases globally, including biologics like Crysvita, Mepsevii, Dojolvi, Evkeeza, and gene therapies, through collaborations with multi...

INDUSTRY

Biotechnology

A PRODUCT ULTRAGENYX PHARMACEUTICAL INC. IS KNOWN FOR

UX111 (rebisufligene etisparvovec)
UX111 (rebisufligene etisparvovec)

UX111 is an investigational AAV9 gene therapy for Sanfilippo syndrome type A, with Ultragenyx resubmitting its BLA to the FDA in January 2026, aiming to be the first approved treatment for this rare neurodegenerative disease.

COMPETITORS

COMPETITOR
DNLI COMPARE
RGNX COMPARE
SRPT COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$94.99M $101.68M ▲$89M ▼$112M ▲
Royalty$64.94M $105.6M ▲$47M ▼$102M ▲

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
North America$83.54M $132.75M ▲$59M ▼$121M ▲
Latin America$43.36M $38.78M ▼$42M ▲$51M ▲
EMEA$27.88M $53.72M ▲$31M ▼$35M ▲
Asia Pacific$5.15M $5.36M ▲$4M ▼$7M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
168
LISTED HERE
26
RANKED BY POSITION SIZE
XBI
0.86% · 3.9M
VTS.AX
0.00% · 3.0M
XSU.TO
0.08% · 2.5M
SCHA
0.05% · 468.1K
FESM
0.13% · 314.5K
PRFZ
0.18% · 194.6K
FYC
0.30% · 167.4K
LABU
0.59% · 141.7K
XRS2.DE
0.08% · 86.6K
HAPS
1.26% · 85.5K
TMSL
0.07% · 81.2K
TMFS
3.03% · 69.6K
GNOM
1.83% · 66.5K
BBP
1.32% · 60.1K
BBSC
0.10% · 28.0K
BIOT.L
2.78% · 25.7K
GSSC
0.03% · 14.5K
RFLR
0.20% · 7.3K
WBIO.L
0.42% · 5.3K
ACSG
0.20% · 4.0K
ESSC
0.27% · 3.9K
URTY
0.03% · 3.9K
STXK
0.10% · 3.3K
BKSE
0.09% · 3.2K
HELX
0.24% · 3.0K
VETS
0.21% · 2.5K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
72.91%
HOLDERS
497
TOP 12 OF 497 · RANKED BY POSITION SIZE
Blackrock, Inc.
10.7M sh · $355.75M
Vanguard Group Inc
10.3M sh · $236.07M
Rtw Investments, LP
7.8M sh · $260.34M
Fmr LLC
7.3M sh · $219.08M
Aqr Capital Management LLC
6.6M sh · $214.14M
State Street Corp
6.2M sh · $205.64M
Blackrock Inc.
5.6M sh · $230.3M
Jpmorgan Chase & Co
4.0M sh · $120.66M
Sands Capital Management, LLC
3.8M sh · $113.4M
Two Sigma Investments, LP
3.6M sh · $120.91M
Sofinnova Investments, Inc.
3.1M sh · $65.91M
Jacobs Levy Equity Management, Inc
2.9M sh · $98.16M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Gilbert Cisneros
Gilbert Cisneros
Purchase
2026-02-18
 Ro Khanna
Ro Khanna
Sale
2022-01-21
 Kurt Schrader
Kurt Schrader
Purchase
2021-08-30

INSIDER TRADES

★
OFFICER: EVP AND CHIEF LEGAL OFFICER
Parschauer Karah Herdman
Sale · 1.9K shares
2026-08-03
★
OFFICER: CHIEF FINANCIAL OFFICER
Horn Howard
Sale · 4.7K shares
2026-08-03
★
OFFICER: CHIEF FINANCIAL OFFICER
Horn Howard
Sale · 4.7K shares
2026-07-01
★
OFFICER: EVP AND CHIEF LEGAL OFFICER
Parschauer Karah Herdman
Sale · 1.9K shares
2026-06-15

MOST RECENT ANALYST GRADES

GRADE SUMMARY
NEUTRAL 1
1 GRADES IN THE LAST 12 MONTHS
Goldman Sachs NEUTRAL

SECTORS PEERS

PEERPRICE
APGE$134.97COMPARE
CGON$74.34COMPARE
TVTX$65.67COMPARE
XENE$59.99COMPARE
DYN$25.07COMPARE
CELC$88.44COMPARE
IDYA$40.11COMPARE
AAPG$18.28COMPARE